SYNOPSYS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SYNOPSYS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 31, 2022 | $5.08B | Dec 12, 2022 |
| FY2022 | Oct 31, 2021 | $4.20B | Dec 12, 2022 |
| FY2022 | Oct 31, 2020 | $3.69B | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $3.36B | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $3.12B | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $2.72B | Dec 20, 2019 |
| FY2016 | Oct 31, 2016 | $633.72M | Dec 12, 2016 |
| FY2016 | Jul 31, 2016 | $615.20M | Dec 12, 2016 |
| FY2016 | Apr 30, 2016 | $605.01M | Dec 12, 2016 |
| FY2016 | Jan 31, 2016 | $568.60M | Dec 12, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $7.05B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $6.13B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $5.32B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $4.62B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $4.20B | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $3.69B | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $3.36B | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $3.12B | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $2.72B | Dec 20, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.43B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $4.88B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $4.29B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $3.72B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $3.34B | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $2.89B | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $2.61B | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $2.39B | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $2.07B | Dec 20, 2019 |
| FY2016 | Oct 31, 2016 | $491.51M | Dec 12, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.33B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $2.26B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.23B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $984.59M | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $757.52M | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $664.35M | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $532.37M | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $432.52M | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $136.56M | Dec 20, 2019 |
| FY2018 | Oct 31, 2016 | $266.83M | Dec 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $914.93M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.36B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.27B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.15B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $734.79M | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $620.14M | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $520.23M | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $360.23M | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $347.56M | Dec 20, 2019 |
| FY2018 | Oct 31, 2016 | $317.40M | Dec 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.48B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $2.08B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.85B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.59B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $1.50B | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $1.28B | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $1.14B | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $1.08B | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $908.84M | Dec 20, 2019 |
| FY2018 | Oct 31, 2016 | $856.71M | Dec 17, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.52B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $1.41B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $1.70B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $1.74B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $1.49B | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $991.31M | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $800.51M | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $424.40M | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $632.48M | Dec 20, 2019 |
| FY2014 | Oct 31, 2014 | $550.95M | Dec 15, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $169.45M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $139.50M | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $189.62M | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $136.59M | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $93.76M | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $154.72M | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $198.13M | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $98.98M | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $70.33M | Dec 20, 2019 |
| FY2018 | Oct 31, 2016 | $66.91M | Dec 17, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $48.22B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $13.07B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $10.33B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $9.42B | Dec 12, 2023 |
| FY2022 | Oct 31, 2021 | $8.75B | Dec 12, 2022 |
| FY2021 | Oct 31, 2020 | $8.03B | Dec 13, 2021 |
| FY2020 | Oct 31, 2019 | $6.41B | Dec 15, 2020 |
| FY2019 | Oct 31, 2018 | $6.15B | Dec 20, 2019 |
| FY2018 | Oct 31, 2017 | $5.40B | Dec 17, 2018 |
| FY2017 | Oct 31, 2016 | $5.24B | Dec 14, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $19.90B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $4.05B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $4.15B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $3.86B | Dec 12, 2023 |
| FY2022 | Oct 31, 2021 | $3.45B | Dec 12, 2022 |
| FY2021 | Oct 31, 2020 | $3.12B | Dec 13, 2021 |
| FY2020 | Oct 31, 2019 | $2.32B | Dec 15, 2020 |
| FY2019 | Oct 31, 2018 | $2.66B | Dec 20, 2019 |
| FY2018 | Oct 31, 2017 | $2.12B | Dec 17, 2018 |
| FY2017 | Oct 31, 2016 | $2.05B | Dec 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $28.33B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $8.99B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $6.15B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $5.52B | Dec 12, 2023 |
| FY2022 | Oct 31, 2021 | $5.30B | Dec 12, 2022 |
| FY2021 | Oct 31, 2020 | $4.91B | Dec 13, 2021 |
| FY2020 | Oct 31, 2019 | $4.08B | Dec 15, 2020 |
| FY2019 | Oct 31, 2018 | $3.48B | Dec 20, 2019 |
| FY2018 | Oct 31, 2017 | $3.28B | Dec 17, 2018 |
| FY2017 | Oct 31, 2016 | $3.20B | Dec 14, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $26.90B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $3.45B | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $3.35B | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | $3.12B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $3.58B | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | $3.37B | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | $3.17B | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | $3.14B | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | $2.71B | Dec 20, 2019 |
| FY2018 | Oct 31, 2016 | $2.52B | Dec 17, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $10.32B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $8.98B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $6.74B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $5.53B | Dec 12, 2023 |
| FY2022 | Oct 31, 2021 | $4.55B | Dec 12, 2022 |
| FY2021 | Oct 31, 2020 | $3.80B | Dec 13, 2021 |
| FY2020 | Oct 31, 2019 | $3.16B | Dec 15, 2020 |
| FY2019 | Oct 31, 2018 | $2.54B | Dec 20, 2019 |
| FY2018 | Oct 31, 2017 | $2.14B | Dec 17, 2018 |
| FY2017 | Oct 31, 2016 | $1.95B | Dec 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.89B | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $3.90B | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $1.43B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $1.42B | Dec 12, 2023 |
| FY2022 | Oct 31, 2021 | $1.43B | Dec 12, 2022 |
| FY2021 | Oct 31, 2020 | $1.24B | Dec 13, 2021 |
| FY2020 | Oct 31, 2019 | $728.60M | Dec 15, 2020 |
| FY2019 | Oct 31, 2018 | $723.12M | Dec 20, 2019 |
| FY2018 | Oct 31, 2017 | $1.05B | Dec 17, 2018 |
| FY2018 | Oct 31, 2016 | $976.62M | Dec 17, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $13.48B | Dec 22, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 8 | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 14 | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | 8 | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | 6 | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | 4 | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | 4 | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | 3 | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | 2 | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | 0 | Dec 20, 2019 |
| FY2016 | Oct 31, 2016 | 0 | Dec 12, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 8 | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 14 | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | 7 | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | 6 | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | 4 | Dec 12, 2023 |
| FY2022 | Oct 31, 2020 | 4 | Dec 12, 2022 |
| FY2021 | Oct 31, 2019 | 3 | Dec 13, 2021 |
| FY2020 | Oct 31, 2018 | 2 | Dec 15, 2020 |
| FY2019 | Oct 31, 2017 | 0 | Dec 20, 2019 |
| FY2016 | Oct 31, 2016 | 0 | Dec 12, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 185.99M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 154.11M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | 152.05M | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | 152.38M | Dec 12, 2023 |
| FY2022 | Oct 31, 2021 | 153.06M | Dec 12, 2022 |
| FY2021 | Oct 31, 2020 | 152.62M | Dec 13, 2021 |
| FY2020 | Oct 31, 2019 | 150.33M | Dec 15, 2020 |
| FY2019 | Oct 31, 2018 | 149.27M | Dec 20, 2019 |
| FY2018 | Oct 31, 2017 | 150.45M | Dec 17, 2018 |
| FY2017 | Oct 31, 2016 | 151.45M | Dec 14, 2017 |